Why Bigger Is Better For Controlling Oncology Spend: It offers less competition - perhaps - but can be a boon for evidence-based pathway initiatives.

Abstract

Oncology practices nationwide face rising maintenance costs and lower reimbursements for biologic therapies. It's even tougher for small community-based practices, which often lag in adopting new standards of cancer care. Group purchasing organizations claim they have the market clout that oncologists need, and McKesson is betting that they are right. Will the US Oncology buyout deliver?